- Trial phase
- Approved
- Time to market
- Already approved and commercially marketed since 1995.
- Why 3/10
- No hard, dated catalyst (PDUFA, pivotal readout, AdComm) is scheduled for VARIVAX in the next ~12 months. It is an already-approved, marketed vaccine with no pending regulatory decision, which per the rubric caps the impact score at 3-5. It is also a very small component of Merck's $65B+ revenue base.
VARIVAX has no upcoming PDUFA date, pivotal readout, or other hard binary catalyst. As a mature, approved vaccine in Merck's broad portfolio, its commercial performance will be reported as part of Merck's quarterly vaccine segment results, but it is unlikely to drive meaningful share-price movement on its own. Investors should watch for any competitive entries or CDC immunization schedule changes that could affect the varicella vaccine market.
Price Chart
Executive Summary
VARIVAX is Merck's live attenuated varicella (chickenpox) vaccine, FDA-approved since March 1995 and the only standalone varicella vaccine available in the U.S. It is a mature, commercially marketed product with no pending regulatory catalysts. Merck is the sole U.S. manufacturer of varicella vaccine (both standalone VARIVAX and combination MMRV vaccine ProQuad). The combined ProQuad/M-M-R II/Varivax franchise generated roughly $538 million in 2026, a small fraction of Merck's $65B+ total revenue. The drug's prescribing information was updated in August 2026, but no near-term binary catalysts exist for this product.
How It Works
VARIVAX is a live, weakened (attenuated) form of the varicella-zoster virus, the virus that causes chickenpox. When injected, it triggers the immune system to produce antibodies and memory cells that protect against future chickenpox infection, without causing the disease itself in healthy people.
Trial Status
VARIVAX was FDA-approved in March 1995 and has been commercially marketed for over 30 years. It is indicated for active immunization against varicella (chickenpox) in individuals 12 months of age and older. The vaccine is administered as a two-dose regimen. Merck updated the prescribing information most recently in August 2026.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for VARIVAX specifically. Merck's quarterly earnings reports will include vaccine segment performance.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report